Article Text

PDF
FRI0358 Contribution of the Adhesion Receptor DNAX Accessory Molecule-1 (DNAM-1) in the Development of Experimental Arthritis
  1. M. Elhai1,
  2. G. Chiocchia2,
  3. F. Lager3,
  4. Y. Allanore1,
  5. J. Avouac1
  1. 1team ATIP/Avenir, Paris Descartes University, Cochin Institut, INSERM U1016 UMR 8104, Cochin Institute, Paris
  2. 2Université Versailles-Saint-Quentin, Versailles
  3. 3Small Animal Imaging Facility, Paris Descartes University, INSERM U1016, Institut Cochin, Sorbonne Paris Cité, Paris, France

Abstract

Background Rheumatoid arthritis (RA) is a frequent disease leading to joint destruction, deformity, and loss of function. Its pathogenesis results from the combination of genetic susceptibility genes and environmental factors. Recently, a non-synonymous single nucleotide polymorphism Gly307Ser (rs763361) in the CD226 gene, encoding the DNAX accessory molecule 1 (DNAM-1), has been associated with different autoimmune diseases including RA. Moreover, the functional role of DNAM-1 has been demonstrated in vivo in animal models of multiple sclerosis and dermal fibrosis.

Objectives We aimed to determine the impact of DNAM-1 in the development of arthritis in vivo in a widely used mouse model: the collagen-induced arthritis (CIA) model, using two complementary approaches: a targeted molecular approach with neutralizing anti-DNAM-1 monoclonal antibody (mAb) and a gene inactivation strategy using mice lacking DNAM-1 (dnam1-/-).

Methods CIA was induced in DBA/1 mice, treated in parallel with a DNAM-1 neutralizing monoclonal antibody, a control IgG and PBS, respectively. CIA was also induced in dnam1-/-mice and control dnam-1+/+ mice on a C57/BL6 background. Mice were monitored for clinical and ultrasound signs of arthritis. Histological analysis was performed to evaluate inflammatory infiltrates and erosions.

Results Clinical evidence of arthritis was observed in 5/7 (71%) mice treated with anti-DNAM-1 mAb, 6/7 (86%) mice treated with control IgG, and 7/7 (100%) mice injected with PBS (p=0.1). There was also a non-significant trend for lower clinical, ultrasound and histological scores in mice receiving anti-DNAM-1 mAb. Although not significant, our results suggested a trend toward a less arthritic phenotype in mice treated with anti-DNAM-1 mAb. However, molecular targeted strategy is characterized by an incomplete blockade of the pathway targeted, unlike the gene inactivation strategy. Therefore to better assess the effect of DNAM-1 inhibition for the prevention of CIA, we performed a gene inactivation strategy using dnam1-/- mice. In all, 7/7 (100%) dnam1+/+ versus 4/5 (80%) dnam1-/- mice developed clinical arthritis (p=0.2). Clinical, ultrasound and histological scores were similar in dnam1+/+ and dnam1-/- mice. Collagen antibodies levels were similar in all mice, confirming immunization with collagen.

Conclusions These complementary approaches failed to demonstrate the implication of DNAM-1 in the development of CIA. These findings do not confirm the results of the genetic studies on the role of DNAM-1 in RA. Further studies are now needed to confirm or not the contribution of DNAM-1 in other autoimmune conditions.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4931

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.